医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Biodynamo, a Start-up, Develops ‘Demenice’, a Smart Watch That Prevents Dementia and Supports Daily Life of Patients with Dementia

2015年11月04日 PM10:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

Biodynamo Co. Ltd (www.biodynamo.net), a start-up developing medical and health solutions in Korea, announced that it developed a smart watch, ‘Demenice’ that prevents dementia and supports daily life of patients with dementia.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151104005651/en/

‘Demenice’ smart watch helps seniors in ages above 60 who have risks of dementia and its patients in early stage prevent and manage the disease by wearing it. The smart watch enables families of its wearers, dementia healthcare providers and dementia healthcare centers to monitor conditions of patients through smart phones or PCs and provide needed support to them based on data transmitted by the smart watch.

Featuring functions of early testing of dementia, cognitive therapy and management of medication, diet, exercise and wandering, ‘Demenice’ can prevent dementia and support daily life of patients with dementia.

Embedded with programs of cognitive rehabilitation treatment, medication management, dietary management, exercise management and location-tracking, the smart watch supports daily life of dementia patients and helps improvement of their symptoms. Among them, the wandering management program that tracks location can prevent missing of patients with dementia.

Biodynamo CEO James Eun said “Serious accidents caused by dementia is increasing, we developed ‘Demenice’ to help daily life of dementia patients and their families.”

Biodynamo developed ‘Demenice’ in collaboration with medical professionals specialized in dementia. Its investigational product is currently in clinical trial and it is scheduled to be launched in the first half of 2016.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151104005651/en/

CONTACT

Biodynamo
James Eun, 82-2-2241-3884
dmswogud@daum.net

同じカテゴリーの記事 

  • Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)
  • Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries
  • Inocras Hong Kong Limited, in Collaboration with Cancerinformation.com.hk Charity Foundation and Sponsored by AstraZeneca Hong Kong, Offers Free BRCA or HRD Genetic Testing for Eligible Cancer Patients in Hong Kong and Macau
  • BrainChip Earns Australian Patent for Improved Spiking Neural Network
  • Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies